Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients.

IF 2.1 3区医学 Q2 OPHTHALMOLOGY

Japanese Journal of Ophthalmology Pub Date : 2023-11-01 Epub Date: 2023-08-19 DOI:10.1007/s10384-023-01022-6

Rei Sakata, Shiro Mizoue, Keiji Yoshikawa, Misato Adachi, Shinji Ohkubo, Naoki Hamada, Tomoko Naito, Tomoyuki Muramatsu, Takeshi Hara, Ryo Asato, Makoto Aihara

{"title":"Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients.","authors":"Rei Sakata, Shiro Mizoue, Keiji Yoshikawa, Misato Adachi, Shinji Ohkubo, Naoki Hamada, Tomoko Naito, Tomoyuki Muramatsu, Takeshi Hara, Ryo Asato, Makoto Aihara","doi":"10.1007/s10384-023-01022-6","DOIUrl":null,"url":null,"abstract":"Purpose: A brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination (BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan. We investigated the efficacy and safety of BBFC used concomitantly with prostaglandin analogs (PG) or a PG/beta-blocker fixed-dose combination (PG/beta FC).Study design: This was a prospective, open-label, multicenter study.Patients and methods: We enrolled Japanese patients with open-angle glaucoma. BBFC (Ailamide) was concomitantly administered to either the PG or the PG/beta FC group, and intraocular pressure (IOP) and safety were evaluated at 4 and 12 weeks. The groups were stratified into low and high IOP baseline groups based on the median baseline IOP.Results: We enrolled 100 patients, 91 of whom completed the 12-week follow-up. The mean ages were 67.1 and 65.7 years in the PG group (n = 45, baseline IOP of 15.7 ± 2.3 mmHg) and the PG/beta FC group (n = 46, baseline IOP of 16.3 ± 2.3 mmHg), respectively. After BBFC administration, IOPs at 4 and 12 weeks were 13.0 ± 2.0 and 13.0 ± 2.6 mmHg (P < 0.0001) in the PG group, respectively, and 13.7 ± 2.4 and 13.7 ± 2.2 mmHg (P < 0.0001) in the PG/beta FC group, respectively. IOP decreased by - 2.0 ± 1.8 mmHg (P < 0.0001) and -1.9 ± 1.4 mmHg (P < 0.0001) in the low baseline PG group (14.1 mmHg) and low baseline PG/beta FC group (14.8 mmHg) at 12 weeks, respectively. Sixteen adverse events were identified, all of which were common and did not affect visual acuity.Conclusions: BBFC can be used concomitantly with PG or PG/beta FC to reduce IOP without serious complications.","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10384-023-01022-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: A brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination (BBFC) was recently approved for glaucoma and ocular hypertension treatment in Japan. We investigated the efficacy and safety of BBFC used concomitantly with prostaglandin analogs (PG) or a PG/beta-blocker fixed-dose combination (PG/beta FC).

Study design: This was a prospective, open-label, multicenter study.

Patients and methods: We enrolled Japanese patients with open-angle glaucoma. BBFC (Ailamide) was concomitantly administered to either the PG or the PG/beta FC group, and intraocular pressure (IOP) and safety were evaluated at 4 and 12 weeks. The groups were stratified into low and high IOP baseline groups based on the median baseline IOP.

Results: We enrolled 100 patients, 91 of whom completed the 12-week follow-up. The mean ages were 67.1 and 65.7 years in the PG group (n = 45, baseline IOP of 15.7 ± 2.3 mmHg) and the PG/beta FC group (n = 46, baseline IOP of 16.3 ± 2.3 mmHg), respectively. After BBFC administration, IOPs at 4 and 12 weeks were 13.0 ± 2.0 and 13.0 ± 2.6 mmHg (P < 0.0001) in the PG group, respectively, and 13.7 ± 2.4 and 13.7 ± 2.2 mmHg (P < 0.0001) in the PG/beta FC group, respectively. IOP decreased by - 2.0 ± 1.8 mmHg (P < 0.0001) and -1.9 ± 1.4 mmHg (P < 0.0001) in the low baseline PG group (14.1 mmHg) and low baseline PG/beta FC group (14.8 mmHg) at 12 weeks, respectively. Sixteen adverse events were identified, all of which were common and did not affect visual acuity.

Conclusions: BBFC can be used concomitantly with PG or PG/beta FC to reduce IOP without serious complications.

Abstract Image

查看原文本刊更多论文

0.1%酒石酸溴莫尼定/ 1%溴唑胺固定剂量联合治疗前列腺素类似物治疗的日本青光眼患者的叠加效应。

目的:0.1%酒石酸溴莫尼定/ 1%溴唑胺固定剂量组合(BBFC)最近在日本被批准用于青光眼和高眼压的治疗。我们研究了BBFC与前列腺素类似物(PG)或PG/ β受体阻滞剂固定剂量组合(PG/ β - FC)联合使用的疗效和安全性。研究设计:这是一项前瞻性、开放标签、多中心研究。患者和方法:我们招募了日本开角型青光眼患者。PG组或PG/ β FC组同时给予BBFC (Ailamide)，并在4周和12周时评估眼压(IOP)和安全性。根据中位基线IOP分为低IOP基线组和高IOP基线组。结果:我们招募了100例患者，其中91例完成了为期12周的随访。PG组(n = 45，基线IOP 15.7±2.3 mmHg)和PG/ β FC组(n = 46，基线IOP 16.3±2.3 mmHg)的平均年龄分别为67.1岁和65.7岁。BBFC给药后第4周和第12周的IOP分别为13.0±2.0和13.0±2.6 mmHg (P)结论:BBFC可与PG或PG/ β FC合用降低IOP，且无严重并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Ophthalmology 医学-眼科学

CiteScore

4.80

自引率

8.30%

发文量

审稿时长

6-12 weeks

期刊介绍： The Japanese Journal of Ophthalmology (JJO) was inaugurated in 1957 as a quarterly journal published in English by the Ophthalmology Department of the University of Tokyo, with the aim of disseminating the achievements of Japanese ophthalmologists worldwide. JJO remains the only Japanese ophthalmology journal published in English. In 1997, the Japanese Ophthalmological Society assumed the responsibility for publishing the Japanese Journal of Ophthalmology as its official English-language publication. Currently the journal is published bimonthly and accepts papers from authors worldwide. JJO has become an international interdisciplinary forum for the publication of basic science and clinical research papers.